Act on Musk’s prediction before November 11

Two deals landed inside 48 hours this week, and the diagnostics sector will not look quite the same on the other side. On October 13, Agilent agreed to pay $240 million in cash at closing, plus up to $30 million in earnouts, for Proscia, a digital pathology software company whose platform ties together slide scanners, laboratory information systems, and AI tools for more than 4,000 labs and 16 of the world’s 20 largest pharmaceutical companies. Two days later, Labcorp agreed to pay up to $872 million for select assets of Opko Health’s BioReference subsidiary.

The headline on both deals is consolidation. The subtext is that the buyers were not chasing testing volume. They were buying data infrastructure and proprietary science. Agilent wanted Proscia’s software operating layer. Labcorp wanted the 4Kscore blood test, which helps predict the likelihood of aggressive prostate cancer before a biopsy decision. The testing capacity was secondary.

The End of a Three-Year Sell-Off

For Opko, this is the close of a long unwind. The October 14 agreement is the third asset buyout between Labcorp and Opko in less than three years, following a $237.5 million purchase of regional clinical assets in 2024 and an up-to-$225 million acquisition of oncology testing businesses in 2025. Opko originally acquired BioReference in 2015 through a stock transaction announced at $1.47 billion, with the strategic ambition that BioReference’s national laboratory infrastructure would accelerate adoption of the 4Kscore test and future diagnostics. Eleven years later, that distribution job belongs to Labcorp.

The latest transaction includes $722 million in cash at closing, with up to $150 million in additional payments tied to 4Kscore revenue over as long as 10 years, and covers clinical and women’s health testing operations, urology and corrections businesses, and certain other operational assets. Labcorp expects the acquired operations to generate approximately $250 million in revenue in the first year post-closing.

What Opko Is Actually Left Holding

Opko’s stock jumped sharply on the announcement. Shares rose 20% in premarket trading. That reaction makes sense if you believe the $722 million in upfront cash, plus the potential earnout, is transformative for a company whose market cap sat around $1 billion heading into the week.

The harder question is what the company looks like once BioReference is gone. For Opko, the sale is intended to streamline operations and allow the company to focus more closely on its biopharmaceutical business. The announcement did not specify how Opko intends to deploy the cash proceeds, whether through debt reduction, pipeline funding, or share repurchases. That ambiguity matters. A 20% pop on deal day is not the same as a durable rerating.

The companies’ releases did not break out what share of Opko’s overall diagnostics revenue or earnings the divested BioReference businesses represent, or what remains at Opko after the deal closes. Investors celebrating the sale proceeds should also be asking what the revenue base looks like the morning after closing.

The Broader Signal

Proscia’s software platform serves as a central operating layer for digital pathology, supporting clinical and life sciences customers across the U.S. and Europe, connecting slide scanners, laboratory information systems, image-analysis applications, AI tools, and data in one unified environment. Agilent was already a commercial partner since 2022; buying the company outright closes a four-year loop and, more importantly, follows its $950 million acquisition of Biocare Medical announced in March 2026. That is two acquisitions in eight months, both aimed at owning the full pathology stack.

Labcorp’s logic is similar. In a note to clients reported by Reuters, William Blair analysts called the 4Kscore test a “particularly compelling asset” with opportunity for broader adoption, noting it could help identify patients for further evaluation and avoid unnecessary biopsies. Owning that test inside a national lab network is a different business than licensing it through a regional operator.

Risks Worth Watching

Labcorp shares fell as investors reacted to the company’s decision to spend up to $872 million, a sizeable cash outlay that raises concerns about integration risk and future returns. Labcorp held $141.8 million in cash and cash equivalents as of June 30, 2026, meaning the deal will require significant financing. Integration of patient service centers across multiple specialties is not a short-term project.

For Opko, the risk runs the other direction. Selling the diagnostics engine that generated the company’s most predictable revenue stream leaves a smaller, less diversified business dependent on a biopharma pipeline that has yet to define its next major catalyst. The stock reacted to the cash. Investors still need to decide whether they like what’s left.